Novel Iron Oxide Nanoparticles Induce Ferroptosis in a Panel of Cancer Cell Lines.
Roberto Fernández-AcostaClaudia Iriarte-MesaDaniel Alvarez-AlminaqueBehrouz HassanniaBartosz WiernickiAlicia M Díaz-GarcíaPeter VandenabeeleTom Vanden BergheGilberto L Pardo-AndreuPublished in: Molecules (Basel, Switzerland) (2022)
The use of nanomaterials rationally engineered to treat cancer is a burgeoning field that has reported great medical achievements. Iron-based polymeric nano-formulations with precisely tuned physicochemical properties are an expanding and versatile therapeutic strategy for tumor treatment. Recently, a peculiar type of regulated necrosis named ferroptosis has gained increased attention as a target for cancer therapy. Here, we show for the first time that novel iron oxide nanoparticles coated with gallic acid and polyacrylic acid (IONP-GA/PAA) possess intrinsic cytotoxic activity on various cancer cell lines. Indeed, IONP-GA/PAA treatment efficiently induces ferroptosis in glioblastoma, neuroblastoma, and fibrosarcoma cells. IONP-GA/PAA-induced ferroptosis was blocked by the canonical ferroptosis inhibitors, including deferoxamine and ciclopirox olamine (iron chelators), and ferrostatin-1, the lipophilic radical trap. These ferroptosis inhibitors also prevented the lipid hydroperoxide generation promoted by the nanoparticles. Altogether, we report on novel ferroptosis-inducing iron encapsulated nanoparticles with potent anti-cancer properties, which has promising potential for further in vivo validation.
Keyphrases
- cell death
- papillary thyroid
- iron oxide nanoparticles
- cell cycle arrest
- pet ct
- cancer therapy
- squamous cell
- drug delivery
- healthcare
- induced apoptosis
- childhood cancer
- squamous cell carcinoma
- transcription factor
- lymph node metastasis
- working memory
- combination therapy
- risk assessment
- oxidative stress
- high glucose
- fatty acid
- drug release
- drug induced
- endoplasmic reticulum stress